Loading...
EIGR.Q logo

Eiger BioPharmaceuticals, Inc.Informe acción OTCPK:EIGR.Q

Capitalización bursátil US$12.6m
Precio de las acciones
n/a
Mi valor justo
No disponible
1Y-5.6%
7D0%
1D
Valor de la cartera
​
Ver

Eiger BioPharmaceuticals, Inc.

Informe acción OTCPK:EIGR.Q

Capitalización de mercado: US$12.6m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Eiger BioPharmaceuticals (EIGR.Q) Resumen de Acciones

Eiger BioPharmaceuticals, Inc, empresa biofarmacéutica en fase comercial, se centra en el desarrollo de terapias contra el virus de la hepatitis delta (VHD) y otras enfermedades graves. Saber más

Análisis fundamental de EIGR.Q
Puntuación del snowflake
Valoración2/6
Crecimiento futuro0/6
Rendimiento pasado0/6
Salud financiera0/6
Dividendos0/6

Análisis de riesgos

Patrimonio neto negativo

Los beneficios han disminuido un 9.7% al año en los últimos 5 años

No tiene una capitalización de mercado significativa ($13M)

Precio de las acciones volátil durante los últimos 3 meses en comparación con el mercado US


EIGR.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Competidores de Eiger BioPharmaceuticals, Inc.

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Eiger BioPharmaceuticals
Precios históricos de las acciones
Precio actual de la acciónUS$8.50
Máximo en las últimas 52 semanasUS$16.00
Mínimo de 52 semanasUS$1.10
Beta2.78
Cambio en 1 mes-15.00%
Variación en 3 meses-24.11%
Cambio de 1 año-5.59%
Variación en 3 años-95.66%
Variación en 5 años-97.13%
Variación desde la OPV-98.22%

Noticias y actualizaciones recientes

Recent updates

Artículo de análisis • Apr 01

Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shareholders that were waiting for something to happen have been dealt a...
Artículo de análisis • Jan 04

The Market Doesn't Like What It Sees From Eiger BioPharmaceuticals, Inc.'s (NASDAQ:EIGR) Revenues Yet As Shares Tumble 26%

Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shareholders won't be pleased to see that the share price has had a very...
Artículo de análisis • Dec 20

Analysts Have Just Cut Their Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Revenue Estimates By 22%

The latest analyst coverage could presage a bad day for Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ), with the...
Artículo de análisis • Nov 09

Analyst Forecasts For Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Are Surging Higher

Shareholders in Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) may be thrilled to learn that the analysts have just...
Artículo de análisis • Oct 06

Rock star Growth Puts Eiger BioPharmaceuticals (NASDAQ:EIGR) In A Position To Use Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Seeking Alpha • Oct 05

Eiger sheds ~20% on abandonment of EUA request for COVID therapy

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a biotech focused on rare and ultra-rare diseases, slipped ~20% pre-market Wednesday after announcing it would not seek an emergency use authorization (EUA) application in the U.S. for COVID-19 therapy peginterferon lambda. The decision followed a pre-EUA meeting the company had requested from the FDA. The agency denied the request citing issues in an investigator-sponsored trial designed to assess different therapeutic agents, including peginterferon, in non-hospitalized patients with mild-to-moderate COVID-19. FDA has determined that “any authorization request based on these data is unlikely to meet the statutory criteria for issuance of an EUA in the current context of the pandemic,” the company said. Instead, the agency has suggested that EIGR consider requesting an end-of-Phase 2 meeting to run a company-sponsored pivotal trial targeted at a Biologics License Application (BLA). EIGR is weighing the next steps, including strategic options to advance peginterferon lambda against respiratory viral agents, including COVID-19. Read: In September, the FDA updated its COVID-19 test policy to cut the number of reviews of EUA requests for diagnostic tests.
Seeking Alpha • Sep 06

Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy

The shares of commercial-stage biotech Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) fell ~21% in the pre-market Tuesday after the company announced that the FDA is uncertain about the regulatory path for COVID-19 therapy peginterferon lambda. The update comes after the company's meeting with the regulator regarding the Phase 3 TOGETHER study for peginterferon lambda aimed at its emergency use authorization (EUA). Following the meeting, the FDA has indicated its uncertainty if the company can meet the requirements for a EUA submission for peginterferon lambda. However, EIGR remains in talks with the FDA as the regulator indicated its intention to consider any new data from the TOGETHER trial to support a EUA while the company plans to further develop the candidate in COVID-19.
Seeking Alpha • Jul 26

Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst

European Commission granted marketing authorization for Zokinvy (lonafarnib) for the treatment of patients with progeria on July 20, 2022. Results from the phase 3 D-LIVR study using Lonafarnib for the treatment of patients with Hepatitis Delta Virus are expected by end of 2022. In March of 2022, a single dose of peginterferon Lambda for Covid-19, reduced the risk of hospitalization or ER visits greater than 6 hours by 50% in a predominantly vaccinated population. An Emergency Use Authorization filing from Eiger BioPharmaceuticals to the FDA for peginterferon Lambda for Covid-19 is possible in 2022. Eiger BioPharmaceuticals (EIGR) is a great speculative biotech play to look into. That's because it has a major catalyst for investors to look forward to at the end of 2022. This would be the readout of the phase 3 D-LIVR study, which is using Lonafarnib for the treatment of patients with Hepatitis Delta Virus ((HDV)). There is potential here to eventually possibly obtain approval for two combinations. These combinations include Lonafarnib and ritonavir and in combination with peginterferon alfa. In addition, this biotech had already received European approval for its treatment Zokinvy (Lonafarnib) for the treatment of patients with progeria. It is the first and only treatment approved in Europe for this specific indication. In addition, another possible catalyst would be Emergency Use Authorization (EUA) for Peginterferon Lambda for Covid-19 infection. The company is engaging with the FDA and intends to submit an EUA application along with the full set of results from the TOGETHER study. It was done in a predominantly vaccinated patient population, so it remains to be seen how well it does if it is ultimately approved. Regardless, I believe EUA could act as a trade opportunity. These are the reasons why I believe that Eiger BioPharmaceuticals is a great speculative biotech play to look into. Lonafarnib Catalyst Expected End Of 2022 Lonafarnib is in clinical development for the treatment of patients with Hepatitis Delta Virus. Hepatitis Delta Virus ((HDV)) or Hepatitis D is a very small circular RNA virus. It is one of the smallest types of virus that infects humans. However, right off the bat I will tell you that it is rare. Why is it rare? That's because in order for the HDV to infect someone, they also have to be carrying Hepatitis B (HBV). That's right, HDV needs HBV in order to infect a person. That's the only way HDV can replicate in liver cells. Those who may be at risk of getting HDV are those who have gone through many blood transfusions and those who are intravenous types of drug abusers. Symptoms of those who have this virus are as follows: Abdominal type pain Nausea Fatigue Being rare, there are roughly only about less than 200,000 people in the United States who have it. Eiger estimates that an HDV product could be about a >$1 billion per year market opportunity. The good news is that this program is already ongoing and still enrolling patients. This is known as the phase 3 D-LIVR study, which is estimated to enroll about 400 patients total. At least 300 patients will be treated with Lonafarnib. There are going to be two arms in the study as follows: All oral arm of LNF (lonafarnib) boosted with RTV (ritonavir) LNF boosted with RTV combined with pegylated interferon-alfa (PEG IFN-alfa) Each of the 2 arms above are going to be compared to placebo. That means in order for this study to be successful, it just needs to meet the primary endpoint compared to placebo. The composite primary endpoint is twofold as follows: Compare composite virologic and biochemical response rate at end of treatment ((EOT)) in patients who receive 50 mg Lonafarnib/100 mg BID Ritonavir versus patients who receive placebo (over 48 weeks) Compare composite virologic and biochemical response rate at end of EOT in patients who receive 50 mg Lonafarnib/100 mg BID Ritonavir and 180 mcg QW PEG IFN-alfa-2a (over 48 weeks)
Seeking Alpha • Jul 20

European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy

Eiger BioPharmaceuticals (NASDAQ:EIGR) on Wednesday said the European Commission had granted a marketing authorization to its treatment Zokinvy (lonafarnib) for progeria, which is a progressive genetic disorder that causes accelerated aging. The specific indication for which Zokinvy was approved was as a breakthrough therapy in children and young adults with Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies. The European approval for Zokinvy is valid in all 27 EU member states as well as Iceland, Liechtenstein and Norway. EIGR says Zokinvy is the first and only treatment approved in Europe for progeria. The therapy was approved by the U.S. FDA in 2020. EIGR stock +2.8% to $8.73 in early trading.

Rentabilidad de los accionistas

EIGR.QUS BiotechsMercado US
7D0%1.2%1.0%
1Y-5.6%34.9%28.7%

Rentabilidad vs. Industria: Los resultados de EIGR.Q fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 34.9% el año pasado.

Rentabilidad vs. Mercado: EIGR.Q obtuvo unos resultados inferiores a los del mercado US, que fueron del 28.7% el año pasado.

Volatilidad de los precios

Is EIGR.Q's price volatile compared to industry and market?
EIGR.Q volatility
EIGR.Q Average Weekly Movement12.9%
Biotechs Industry Average Movement11.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Precio estable de las acciones: El precio de las acciones de EIGR.Q ha sido volátil durante los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de EIGR.Q ha disminuido de 39% a 13% en el último año, pero sigue siendo superior al 75% de los valores de US.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
n/a25David Apelianwww.eigerbio.com

Eiger BioPharmaceuticals, Inc, empresa biofarmacéutica en fase comercial, se centra en el desarrollo de terapias contra el virus de la hepatitis delta (VHD) y otras enfermedades graves. La empresa ofrece Zokinvy para el tratamiento del síndrome de progeria de Hutchinson-Gilford y las laminopatías progeroides con deficiencia de procesamiento. Sus productos candidatos incluyen Lonafarnib, un inhibidor de la farnesilación disponible por vía oral, que ha completado los ensayos clínicos de fase 3 para la infección por el VHD; Peginterferón Lambda (lambda), que está en desarrollo clínico para el VHD; lambda, que está en estudios de fase II y III de investigadores de COVID-19 leve y moderada; y Avexitide, que está en fase II para el tratamiento del hiperinsulinismo congénito y la hipoglucemia postbariátrica.

Resumen de fundamentos de Eiger BioPharmaceuticals, Inc.

¿Cómo se comparan los beneficios e ingresos de Eiger BioPharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de EIGR.Q
Capitalización bursátilUS$12.59m
Beneficios(TTM)-US$74.96m
Ingresos (TTM)US$15.77m
0.8x
Ratio precio-ventas (PS)
-0.2x
Ratio precio-beneficio (PE)

¿Está EIGR.Q sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de EIGR.Q
IngresosUS$15.77m
Coste de los ingresosUS$24.00k
Beneficio brutoUS$15.75m
Otros gastosUS$90.71m
Beneficios-US$74.96m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)-50.62
Margen bruto99.85%
Margen de beneficio neto-475.26%
Ratio deuda/patrimonio-284.4%

¿Cómo se ha desempeñado EIGR.Q a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2024/10/02 18:54
Precio de las acciones al final del día2024/10/01 00:00
Beneficios2023/12/31
Ingresos anuales2023/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Eiger BioPharmaceuticals, Inc. está cubierta por 11 analistas. 0 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Madhu KumarBaird
Brian SkorneyBaird
Madhu KumarB. Riley Securities, Inc.